arsenic has been researched along with losartan potassium in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Thorling, EB | 1 |
| Gisslinger, H; Kees, M | 1 |
| Mehta, J; Pichardo, D; Rosen, S; Singhal, S | 1 |
| Baldus, C; Hofmann, WK; Thiel, E; Uharek, L | 1 |
| Emi, N; Kajiguchi, T; Naoe, T; Sawa, M; Yamamoto, K | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Haque, MA; Inoue, R; Kiriyama, N; Nakagawa, H; Nishimura, K; Ogawa, K | 1 |
3 review(s) available for arsenic and losartan potassium
| Article | Year |
|---|---|
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2003 |
Current treatment options and strategies for myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Blood Transfusion; Clinical Trials as Topic; Comorbidity; Disease Progression; Erythropoietin; Farnesyltranstransferase; Hematinics; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Oxides; Recombinant Proteins; Social Class; Stem Cell Transplantation | 2008 |
1 trial(s) available for arsenic and losartan potassium
| Article | Year |
|---|---|
Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reticulocyte Count | 2005 |
3 other study(ies) available for arsenic and losartan potassium
| Article | Year |
|---|---|
A comparison of the cobalt, methylene blue, zinc, arsenite and amino triazole effect on erythropoietin production.
Topics: Animals; Arsenic; Biological Assay; Cobalt; Erythropoietin; Female; Hypoxia; Iron; Iron Isotopes; Male; Methylene Blue; Mice; Polycythemia; Rabbits; Stimulation, Chemical; Triazoles; Zinc | 1973 |
Therapeutic spectrum in the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes; Oxides; Transplantation, Autologous; Transplantation, Homologous | 2004 |
Effect of pentavalent inorganic arsenic salt on erythropoietin production and autophagy induction.
Topics: Animals; Arsenates; Arsenic; Arsenicals; Autophagy; Erythropoietin; Hep G2 Cells; Humans; Rats | 2023 |